Latham & Watkins, Torys LLP and Goodwin represented Triumvira Immunologics in the transaction.Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
